Company Overview and News

79
INFI / Infinity Pharmaceuticals, Inc. 8-K (Current Report)

2018-06-14 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
INFI

69
INFI / Infinity Pharmaceuticals, Inc. null

2018-06-13 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C<@,"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S$Y M-S8O3R [email protected],C
INFI

72
INFI / Infinity Pharmaceuticals, Inc. null

2018-06-12 sec.gov
CORRESP May 8, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E.
INFI

93
Infinity Pharmaceuticals (INFI) Down 6.7% Since Earnings Report: Can It Rebound?

2018-06-07 zacks
A month has gone by since the last earnings report for Infinity Pharmaceuticals, Inc. (INFI - Free Report) . Shares have lost about 6.7% in that time frame.
INFI ENL CRAI ENDP

82
Infinity (INFI) Incurs In-Line Loss in Q1, Maintains View

2018-05-09 zacks
Infinity Pharmaceuticals, Inc. (INFI - Free Report) reported a loss of 18 cents per share in first-quarter 2018, in line with the Zacks Consensus Estimate. The company had reported a loss of 21 cents in the year-ago quarter.
LGNDZ INFI ODP GM.WS.A GM.WS.B LGNZZ LGND GM.WS.C LGNYZ LGNXZ PTGX GM GM.WSB

70
Infinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals Conference Call to discuss the Company's Financial Results for the First Quarter of 2018. My name is Jimmy and I will be your operator for today's call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at Infinity’s request.
INFI

78
INFI / Infinity Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-05-08 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
INFI

69
BRIEF-Infinity Pharmaceuticals Q1 Loss Per Share $0.18

2018-05-08 reuters
* INFINITY PHARMACEUTICALS SAYS FOR THREE MONTHS ENDED MARCH 31, 2018, DILUTED LOSS PER COMMON SHARE WAS $0.18 - SEC FILING
INFI

73
INFI / Infinity Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-05-08 sec.gov
Document Table of Contents
INFI

147
Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates

2018-05-03 zacks
Conatus Pharmaceuticals Inc. (CNAT - Free Report) has incurred first-quarter 2018 loss of 17 cents per share, in line with the Zacks Consensus Estimate and wider than the year-ago loss of 14 cents.
INFI RSG CNAT LGNZZ LGND LGNYZ AVP NVS LGNXZ LGNDZ

111
Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y

2018-05-03 zacks
Acorda Therapeutics, Inc. (ACOR - Free Report) reported adjusted earnings of 14 cents per share in the first quarter of 2018, which significantly missed the Zacks Consensus Estimate of 73 cents. However, the company incurred a loss of 8 cents a year ago.
INFI ACOR OMED RSG LGNZZ LGND LGNYZ AVP LGNXZ LGNDZ

88
INFI / Infinity Pharmaceuticals, Inc. S-3

2018-04-30 sec.gov
S-3 Table of Contents As filed with the Securities and Exchange Commission on April 30, 2018 Registration No. 333-
INFI

158
Allergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/Y

2018-04-30 zacks
Allergan plc’s (AGN - Free Report) first-quarter 2018 earnings came in at $3.74 per share, beating the Zacks Consensus Estimate of $3.36 by 11.3%. The bottom line also rose 11.6% year over year, driven by higher revenues and lower operating costs. Earnings also surpassed the previously expected range of $3.20-$3.40.
INFI OMED AGN CNA LGNZZ LGND LGNYZ LGNXZ LGNDZ

114
Medicines Company's (MDCO) Q1 Loss Widens, Revenues Tank Y/Y

2018-04-27 zacks
The Medicines Company (MDCO - Free Report) incurred first-quarter 2018 loss of 76 cents per share, wider than the Zacks Consensus Estimate of a loss of 71 cents and the year-ago figure of a loss of 75 cents.
INFI LMT LGNZZ LGND LGNYZ MDCO LGNXZ MLNT LGNDZ ALNY

148
AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains

2018-04-26 zacks
AbbVie Inc. (ABBV - Free Report) posted impressive results in the first quarter of 2018 with better-than-expected earnings and revenues. Moreover, the company raised its expectations for 2018 bottom line. In response, shares too climbed almost 2.5% in pre-market trading.
INFI JNJ LGNZZ LGND LGNYZ KO LGNXZ ABBV UTX LGNDZ ABBV

INFI : Infinity Pharmaceuticals Stock Analysis and Research Report

2017-11-07 - Asif

Infinity Pharmaceuticals is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity Pharmaceuticals is focusing its efforts on advancing IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma. Preclinical research has demonstrated that PI3K-gamma is highly expressed in tumor-associated macrophages and that blockade of PI3K-gamma signaling by treatment with IPI-549 results in a reprogramming of macrophages in the tumor microenvironment from the M2, or pro-tumor, phenotype to the M1, or anti-tumor, phenotype. This shift increased the number and activity of anti-tumor T cells that can attack the tumor and also increased the production of pro-inflammatory cytokines, which can further stimulate an anti-tumor immune response. Preclinical data from multiple solid tumor models demonstrated that IPI-549 was active as a monothe...

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to INFI / Infinity Pharmaceuticals, Inc. on message board site Silicon Investor.

Infinera Infineon Technologies
Infinity Pharmaceuticals Infinity Pharmaceuticals Inc (INFI)
From Here to InfiniBand Infinity Broadcasting(CBS)
Chemical biology IFLB - Infinium Labs, Inc.
Calian Technology a Company with infinite growth potential Infinite Group (IMCI)
CUSIP: 45665G303